Northwire Canada EditionFriday, July 24, 2026
Northwire
AVX 0.005 −nan% AII 19.91 −1.0% GWM 0.480 +0.0% GEN 0.065 +0.0% NIO 0.135 −3.6% III 7.22 −2.8% NCAU 0.295 −3.3% NEV 0.040 +0.0% ITR 3.00 −1.6% ALDE 2.79 −0.7% TECK 84.18 +4.4% FVI 11.83 −2.2% SUM 1.31 −1.5% RSMX 0.115 +4.5% STW 0.105 +5.0% PAT 0.250 +0.0% AVX 0.005 −nan% AII 19.91 −1.0% GWM 0.480 +0.0% GEN 0.065 +0.0% NIO 0.135 −3.6% III 7.22 −2.8% NCAU 0.295 −3.3% NEV 0.040 +0.0% ITR 3.00 −1.6% ALDE 2.79 −0.7% TECK 84.18 +4.4% FVI 11.83 −2.2% SUM 1.31 −1.5% RSMX 0.115 +4.5% STW 0.105 +5.0% PAT 0.250 +0.0%
Financings

Quantum licensee begins $5-million (U.S.) raise

QNTM · Price

Executive Summary

  • Unbuzzd Wellness Inc., a licensee of Quantum Biopharma Ltd., has commenced a Regulation D 506(c) capital raise campaign to fund growth and establish a path to a potential initial public offering (IPO).
  • The offering aims to raise up to $5.0 million (U.S.) from accredited investors, with investments accepted via traditional payments or cryptocurrency through ALT5 Pay.
  • Quantum Biopharma states the offering will not dilute its shareholders due to an anti-dilution provision maintaining its 25% ownership stake in Unbuzzd Wellness until the company reaches a $1-billion valuation.

Key Details

  • Capital Raise Structure: Regulation D 506(c) offering.
  • Target Amount: Up to $5.0 million (U.S.).
  • Purpose of Funds: Finance growth, direct-to-consumer expansion, distributor and retail expansion, and establish a path to a possible IPO.
  • Investor Type: Accredited investors only.
  • Payment Methods: Traditional payments or cryptocurrency payments via ALT5 Pay’s digital payments platform.
  • Partners: MZ Digital (marketing) and Dealmaker (capital raising platform).
  • Quantum Biopharma Ownership Terms:
    • Maintains an anti-dilution provision ensuring 25% ownership in Unbuzzd Wellness until Unbuzzd reaches a $1-billion (U.S.) valuation.
    • Current ownership stake: 20.11% (as of March 31, 2025).
    • Upon Unbuzzd going public, Quantum Biopharma will access non-dilutive capital through its ownership.
  • Royalty Agreement:
    • Quantum Biopharma receives 7% of sales from Unbuzzd until total payments reach $250 million.
    • After the $250 million threshold is met, the royalty drops to 3% in perpetuity.
    • Quantum Biopharma retains 100% of rights to develop similar products or alternative formulations for pharmaceutical and medical uses.

Notable Quotes

  • John Duffy, CEO of Unbuzzd Wellness: "This capital raise allows us to introduce investors to a new era in functional beverages aimed at supporting overall wellness after social occasions. Unbuzzd is a refreshing, science-backed beverage that helps people feel more refreshed and alert after drinking. This offering will help us raise the necessary capital to support direct-to-consumer, distributor and retail expansion plans."
  • Gerry David, Board Co-Chair of Unbuzzd Wellness: "Together with our partners MZ Digital, a global leader in on-line marketing, and Dealmaker, a leading on-line platform for raising capital, we are excited to launch this offering to build our company and sales momentum, and position Unbuzzd for a future initial public offering."
Read the original news release →

More from Quantum Biopharma Ltd